Physician profile
Daniel E Harrison
NPI 1104357631
$1,303.89
in general payments reported to CMS, 2019-2025
16 companies · $801 in 2025
The $801 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $304 · 2024: $199 · 2025: $801.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,067 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,066.56 |
| Education | $237.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $467.14 | 2023-2025 | Ensite, Thoratec Heartmate 3 Lvas Implant Kit, Merlin@Home |
| E.R. Squibb & Sons, L.L.C. | $106.54 | 2024-2025 | Camzyos, Eliquis |
| Merck Sharp & Dohme LLC | $105.76 | 2024-2025 | Verquvo |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $103.36 | 2024-2025 | Lifevest |
| Endotronix, INC. | $99.77 | 2025 | Cordella Pulomonary Artery Pressure Sensor |
| Astrazeneca Pharmaceuticals LP | $88.47 | 2025 | Farxiga |
| Edwards Lifesciences Corporation | $59.88 | 2024-2025 | The Edwards Sapien 3 Valve With Alterra Adaptive Prestent System |
| Impulse Dynamics (USA) INC. | $57.98 | 2025 | Optimizer |
| Novo Nordisk INC | $57.56 | 2025 | Wegovy |
| Amgen INC. | $36.04 | 2024-2025 | Repatha |
| Pfizer INC. | $22.14 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.11 | 2025 | Jardiance |
| Kiniksa Pharmaceuticals International, Plc | $20.99 | 2024 | Arcalyst |
| Atricure, INC. | $19.67 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.47 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ancora Heart, INC. | $18.01 | 2025 | Accucinch |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Harrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.